Immunovant
IMVT
215 hedge funds and large institutions have $2.75B invested in Immunovant in 2026 Q1 according to their latest regulatory filings, with 46 funds opening new positions, 93 increasing their positions, 40 reducing their positions, and 25 closing their positions.
619% more call options, than puts
Call options by funds: $61.3M | Put options by funds: $8.52M
133% more repeat investments, than reductions
Existing positions increased: 93 | Existing positions reduced: 40
84% more first-time investments, than exits
New positions opened: 46 | Existing positions closed: 25
9% more funds holding
Funds holding: 197 → 215 (+18)
1% less capital invested
Capital invested by funds: $2.76B → $2.75B (-$15.2M)
7.65% less ownership
Funds ownership: 61.98% → 54.34% (-7.6%)
13% less funds holding in top 10
Funds holding in top 10: 8 → 7 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
TCG Crossover Management
Palo Alto,
California
|
+$72.4M |
| 2 |
Jennison Associates
New York
|
+$64.6M |
| 3 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$39.7M |
| 4 |
State Street
Boston,
Massachusetts
|
+$19.4M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$15M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$56.5M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$50.8M |
| 3 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
-$37.5M |
| 4 |
Morgan Stanley
New York
|
-$25.1M |
| 5 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$22.8M |
IMVT Hedge Fund Activity: Q1 2026 in Review
215 of the 8,187 institutional investors tracked by Wall St. Rank reported a position in Immunovant (IMVT) for Q1 2026, worth a combined $2.75B — down 0.55% from $2.76B a quarter earlier.
Buyers outnumbered sellers: 46 funds opened new IMVT positions and 25 closed out — a net gain of 21 holders — while 93 added to existing stakes and 40 trimmed.
The largest buyer was TCG Crossover Management, adding an estimated $72.4M. The largest seller was Armistice Capital, cutting an estimated $56.5M.
- 215 institutional investors held Immunovant (IMVT) as of Q1 2026, up from 197 in Q4 2025.
- Funds reported $2.75B of Immunovant stock for Q1 2026, down 0.55% quarter-over-quarter.
- 46 funds opened new Immunovant positions in Q1 2026 and 25 closed out, a net change of +21 holders.
- The largest Immunovant buyer in Q1 2026 was TCG Crossover Management, an estimated $72.4M added.
- The largest Immunovant seller in Q1 2026 was Armistice Capital, an estimated $56.5M sold.
Based on aggregated 13F filings for Q1 2026.